Navigation Links
Lilly's CEO Calls for Reform of Nation's Drug Safety System
Date:10/2/2007

FDA, health care industry, and the medical community collaboration would

share data via a national health IT system

CLEVELAND, Oct. 2 /PRNewswire-FirstCall/ -- Sidney Taurel, chairman and chief executive officer, Eli Lilly and Company (NYSE: LLY), in a speech today at the Cleveland Clinic, called on the health care industry, medical community and U.S. government to actively collaborate on a health information technology system that would provide more rapid and useful insights on the effectiveness of medicines while improving drug safety.

His proposal, along with other benefits that would flow from a true healthcare "Information Revolution," was outlined for an audience of some of the nation's medical thought-leaders attending Cleveland Clinic's 2007 Medical Innovations Summit. Taurel was the keynote speaker.

"The use of prescription medicines always will be a matter of balancing benefits and risks," Taurel said. "Fortunately, systems are now within our grasp to more quickly identify both the true benefits and the full extent of risks associated with medicines in widespread use."

Although traditional drug trials will continue to test new hypotheses about medicines after they have reached the market, Taurel outlined how a well-functioning health IT system could serve not only to frame hypothesis for so-called "Phase IV" clinical research, but also become the practical equivalent of massive, real-world trials. Such a system would collect detailed data from day-to-day medical practices and feed insights quickly, seamlessly and at a lower cost to doctors, regulators, and drug manufacturers. The result would be a more accurate picture of a drug's safety and efficacy than exists today.

Taurel also explained that intent of the newly enacted FDA Amendments Act of 2007 is to promote much wider involvement of health plans, academic medical centers and other sponsors in Phase IV research.

"The time is ripe for FDA, the health care industry, and the medical community to collaborate on a reform of our nation's pharmacovigilance system," said Taurel. "Such reform will allow us to speed up the recognition of safety signals and understand the true efficacy of new medicines more quickly."

Taurel noted that to fully realize a better drug safety system would require the large-scale implementation of Electronic Medical Records (EMRs) - patient-specific repositories of clinical information on diagnoses, treatments, and outcomes. Properly "blinded" to protect patient privacy, EMRs ultimately could include genetic information as well, in order to tailor therapies to patient groups in which they work best. He traced some of the obstacles to implementing robust, secure EMRs, and offered solutions.

Taurel explained that as EMR systems build out, they provide what amounts to a 'commons' in which organizations can collaborate to share health information.

For example, Lilly, Pfizer, and Johnson & Johnson are collaborating with 'e-Health Initiative' - a not-for-profit health information technology group - as well as with the Indiana Health Information Exchange and the Partners Healthcare System in Boston. The goal is to test how safety signals can be located and understood using existing data, potentially leading to a better understanding of the risk and benefits of medicines.

"This sort of public-private experiment, along with national standards and regional expansion, will soon create a mass of basic infrastructure that could produce the sort of knowledge that will truly revolutionize patient care," concluded Taurel. "We need to open our minds to the notion that electronic health care data represents a legitimate resource - to which access should in most cases be widespread and easy."

Those attending the talk included clinical, medical affairs and regulatory and business development executives, senior executives at medical device makers and pharmaceutical companies, investment bankers, investors and venture capitalists, researchers and the press.

About the Cleveland Clinic's Medical Innovations Summit Please go to http://www.clevelandclinic.org/innovations/summit/default.htm.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Calls to combat deafness after chemotherapy
2. WHO Calls For Greater Emphasis On Combating AIDS
3. PCT Calls Upon Doctor To Delay Surgeries
4. UN Calls For More Funds For Earthquake Affected
5. MP Calls For Ban On Aspartame
6. Scientist Calls Upon Media To Retract His Work
7. CMHA Calls For Better Trained Police For Dealing With The Mentally Ill
8. US Government Calls For Better Drug Supplies
9. Phone Calls Lend Vital Support to Moms of Mentally Ill Children
10. Report Calls For Better Implementation Of Last Wishes of Terminally Ill
11. Mixed Orientation Marriages Calls for Deeper Understanding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: